Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

Inclusion Criteria: * Enrolled in LEVP2005-1 (current or in the past) Exclusion Criteria: * C1 inhibitor infusion within the last 7 days * Signs of any HAE attack * HAE attack within 7 days before actual infusion of C1INH-nf * Change in the dosage of androgens in the last 14 days before the study * Use of antifibrinolytics in the last 7 days before the study * Change in oral conceptive medication in the last two months before the study * History of clinically relevant antibody development to C1 inhibitor * Use of oral anticoagulant medication in the last 14 days * Use of heparin within the last two days prior to the study * History of allergic reaction to C1 inhibitor or other blood products * Current participation (or within the past 90 days) in any investigational drug study other than those sponsored by Lev Pharmaceuticals * Pregnancy or lactation * B-cell malignancy * Any clinically significant medical condition, such as renal failure, that in the opinion of the investigator would interfere with the subject's ability to participate in the study